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Abstract
Background: Recent deaths of young Australian music festival attendees from ‘party-drug’ overdoses have sparked
debate about the effectiveness of drug policies. Australia is widely lauded for its harm minimisation approach to
drugs, and yet, over the last 30 years, it can be argued its policies have been fragmented, sometimes inconsistent
and contradictory. The present article examines the root of this inconsistency, using it as a foundation to advocate
for drug policy reform. In keeping with the goals of the National Drug Strategy to promote policy innovation, there
is an opportunity to learn from international studies which have shown promising findings in the reduction of
party-drug use and its harms through application of pill testing.
Method: This paper evaluates Australia’s National Drug Strategy and pill testing through a lens of pragmatism, to
determine whether there is space for testing practices in contemporary policy. Specifically, the paper analyses
current drug policy literature and research studies, examining a range of key drug use indicators, social and political
debate and research evidence.
Results: The need for policy reform, attitudinal and cultural shifts and development of stronger cross-sectoral
partnerships is highlighted, to ensure a rational and logical approach that genuinely tackles drug policy-making and
strategy from a broad public health perspective.
Conclusions: Using a theoretical frame of pragmatism and drawing from national and international research
evidence, this paper recommends the integration of pill testing into Australia’s harm minimisation strategy.
Keywords: Pill testing, Harm minimisation, Pragmatism, Australian drug policy, Party-drug use
Background
Young people have long been associated with drug
consumption, often displaying patterns of use distinct
from the general population [1–3]. Like many other coun-
tries, the emergence of dance-music culture and ‘raves’ in
Australia in the 1970–1980s bolstered the relationship be-
tween drugs and youth, creating dynamic settings in
which consumption of so-called ‘party-drugs’ such as
methamphetamines, ecstasy and other psychoactive sub-
stances has become common [4, 5]. For many young
people (i.e. 18–29 years old), attendance at dance-parties
and music festivals is a rite of passage within a hedonistic
lifestyle where identity and social capital are built, pleasure
is ‘consumed’ and alcohol and other drugs (AODs) are
ubiquitous. However, youth party-drug use is typically
viewed by politicians, criminal justice professionals and
the community as deviant, linked to risk-taking, transgres-
sion and individual corruption [6], manifest in a range of
physical, psychological and social harms [1]. Indeed, there
have been several deaths of young music festival attendees
in Australia [7–9], which have held youth party-drug use
at the forefront of political, social and media agendas.
However, notwithstanding the tragic loss of young lives,
what is concerning is that these fatal overdoses, and sev-
eral ‘near-misses’, may have been avoided through more
pragmatic and amoral drug policy and practice. Pill testing
offers an alternative, yet it remains at the fringe of policy
debate, shrouded by punitive praxis and government reti-
cence despite support in the community.
Policy and practical ‘problems’
Similar to recent experiences in the UK [10, 11] and
Europe [12], Australian AOD policy is at a significant
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juncture. At the policy level, the implementation of the
seventh iteration of the National Drug Strategy (NDS)
demonstrates commitment to consistent, ongoing na-
tional drug policy [13] in response to the problem of
drugs, both illicit and illicitly used (i.e. pharmaceuticals,
alcohol and tobacco), under the philosophy of harm
minimisation. The NDS outlines a series of principles
addressing this philosophy, which prioritise delivery of
evidence-informed responses, collaborative interdiscip-
linary partnerships and a trifurcated approach targeting
demand, supply and harm reduction [13]. With regard
to party-drugs, however, the application of this policy is
contested. While the NDS claims the ‘balanced adoption
of effective demand, supply and harm reduction strat-
egies’ ([13]:1), in practice, the distribution of resources,
action and policy reform across its ‘three pillars’ falls
short of this claim. As discussed below, there are consid-
erable funding gaps in AOD treatment [14], zero-
tolerance remains the bastion of public policy and
resources are principally expended on law enforcement
[15, 16]. While in practice, it is not an either/or
approach to supply, demand and harm reduction, nor
are these domains mutually exclusive, clearly a balanced
approach has not yet been achieved.
At the practical level, problems exist regarding the
capacity of policy to recognise and respond to emerging
patterns of problematic use, where novel, unknown
drugs have entered markets [17] at a time when regular
users have increased consumption of more potent forms,
such as ice (crystal methamphetamine) and MDMA
(3,4-methylenedioxymethamphetamine) [18, 19]. The
current framework does not fully capture these nuances,
constrained by hegemonic notions of abstinence. In-
stead, the goal should be to reduce the harms that occur
when people use these unknown or more potent drugs,
given the serious risks. Notably, despite law enforcement
efforts and legislative changes [20], current harm reduc-
tion initiatives have been largely ineffective [21, 22],
evident in monitoring data where certain groups of
young people appear to resist social controls by continu-
ing to use party-drugs. As noted in previous studies
[23–25], this is because many young people see drugs as
playing a normative and peripheral role in their lives,
revealing an important transition in patterns of use,
where party-drugs have become more mainstream, used
by a heterogeneous cohort of ordinary young people
[25]. This apparent normalisation has occurred alongside
a trend where some users are unaware of what they are
taking, engaging in ‘opportunistic’ purchases of drugs at
clubs or music festivals rather than prior to events from
more trusted networks [26].1 Although no use is ‘safe’,
these ad hoc practices substantively increase the risks as
suppliers are more likely to be strangers, who may have
a greater propensity to adulterate drugs with cheaper
and/or alternative substances [28, 29]. Reports have
increased of ecstasy pills containing large amounts of
methamphetamine [30] and other toxic substances (e.g.
rat poison), with others recorded as very high-purity
[18], which could seriously harm users. In combination,
the rise in problematic patterns of use, the emergence of
novel substances and imbalanced policy highlight the
need for targeted and more pragmatic responses to
youth drug use.
Pill testing/drug checking
Pill testing is a harm reduction strategy used inter-
nationally, also known as drug checking or adulterant
screening [31, 32], which emerged in the early 1990s in
the Netherlands [33] where it is now part of official
national policy. Similar initiatives have since been imple-
mented in other European nations including Sweden,
Switzerland, Austria, Germany, Spain and France, albeit
primarily administered and funded privately [12, 34].
Organisations such as DanceSafe also operate in the
USA focused on harm reduction through peer-
education, where a language of pragmatism has been
established [34, 35]. Testing involves dance-party and
music festival attendees volunteering a sample of their
drugs for analysis by scientists, who provide information
concerning composition and purity [32]. In Europe, this
is typically undertaken in mobile facilities located near
or inside venues to allow timely feedback to users
(approx. 30 min). Results are then ‘posted’ anonymously
on information boards or event websites (often using
red/yellow/green colour-coding), so users can review
feedback clearly and discreetly. These practices are pos-
sible through partnerships between event promoters,
healthcare services and local police and a strong harm
reduction philosophy [36, 37]. Most importantly, this
approach has the capacity to influence consumption
behaviour where, in contrast to relying on the strength
of broad anti-drug campaigns, testing in situ can alter
behaviour at the time of consumption, primarily shaped
by peers and social networks [38], including health
workers [39, 40]. Testing can also involve offsite analyses
prior to events, encouraging planning among users,
though it is less common as these services often require
users to provide identification, increasing the perceived
risks of being identified by police [41].
Pill testing is well supported at the local level in
Europe, with self-report data from users, accounts from
key stakeholders (including police) and wider commu-
nity endorsement that it provides ‘safer’ drug settings by
warning users about harmful and/or unexpected sub-
stances [34, 41]. Although research on its effectiveness is
mixed (discussed below), there is practical evidence that
pill testing has helped to reduce overdose frequency,
improve healthcare services, and increase knowledge of
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harm reduction principles [34, 41, 42]. Increased publi-
city for support services, advocacy for public health
campaigns and opportunities for monitoring and re-
search are further benefits observed internationally,
which have fostered evidence-informed and more effect-
ive prevention and treatment [34, 36]. These outcomes
have also served to extend discussion beyond notions of
individual criminality and morality to encompass social,
economic and welfare debates, challenging conventional
thinking about concepts like harm, risk and social
responsibility by considering social contexts of drug use
to understand the relationship that individuals and envi-
ronments have on drug-related harms [43]. It is import-
ant, however, to emphasise that drug use is dangerous
and cannot be conceptualised as risk-free, nor is pill test-
ing a ‘silver bullet’, with some well-documented concerns
[44]. Instead, this article argues that pill testing needs to
be viewed through a lens of pragmatism, where for cer-
tain users in certain settings, it is about providing young
people with information about drugs and their use so
they can make more informed choices to limit the asso-
ciated harms, as well as making important practical
changes to the settings in which drugs are used.
As discussed herein, such thinking appears confront-
ing within the Australian drug policy landscape, where
current discourse is dominated by dogma, moral conflict
and criminal justice debate. Yet, this has not always been
the case, as Australian drug policy has a fragmented his-
tory [45–47], shaped by the changing vagaries of various
political, social and moral forces. The aim therefore is to
determine whether pill testing ‘fits’ within this larger
narrative and lay the foundation for more cogent drug
policy, providing a valuable national framework that may
be applicable to other international policy settings.
Through this lens, the article examines Australia’s drug
policy framework, evaluating a range of key indicators,
current social and political debates, and contemporary
research evidence. Together with discussion of previous
examples of rational policy-making, this data will be
used to offer support and provide a roadmap for imple-
mentation of pill testing as a more pragmatic strategy
and to contribute to discussion of harm minimisation.
Methods: The National Drug Strategy:
fragmentation, contradiction and pragmatism?
The question of how pill testing would fit within the
NDS is thought-provoking because arguably, it could
already. The NDS outlines Australia’s response to alco-
hol, tobacco and other (illicit) drugs and provides a na-
tional framework for coordinated action to limit their
use and associated harms [1]. The strategy has been
committed to this approach since its inception in 1985,
established then as the National Campaign Against Drug
Abuse (NCADA). As noted in the introduction, the
overarching focus and language of the NDS has been the
improvement of public health and minimisation of
harms associated with drug use [1, 19]. This was a sub-
stantive ideological shift away from traditional concep-
tualisations of drug use and drug users, which prior to
the 1980s were often viewed in terms of disease meta-
phors (i.e. as ‘sick’) or as the behaviour of a deviant
underclass [48]. In this way, harm minimisation was a
pragmatic response that sought to shift debate (and
policy-making) away from moral judgements about drug
use [49]. It was a pivotal moment in Australian policy,
signifying the recognition that because drugs have
become a persistent feature of contemporary society, an
innovative approach was needed to reduce drug-related
harms, rather than simply criminalise users. Demonstrat-
ing this, one of the priorities of the 2017–2026 strategy
is to prevent and reduce adverse health, social and eco-
nomic consequences associated with AOD use, by
‘providing opportunities for intervention amongst
high prevalence or high risk groups and locations,
including the implementation of settings-based
approaches to modify risk behaviours…systems to
facilitate greater diversion into health interventions
from the criminal justice system, particularly for…
young people and other at-risk populations who may
be experiencing disproportionate harm…[and a]…
focus on evidence-based strategies shown to reduce
alcohol and other drug hospital presentations, reduce
the spread of blood-borne virus, decrease road
trauma…and decrease overdose risk, with translation
of this evidence to address new and emerging issues’
([13]:23, emphasis added).
Many of these goals are consistent with the rationale for
pill testing. So, while their achievement using this
approach would not be without difficulty and would
require cooperation between law enforcement, health
and community sectors, such interdisciplinary partner-
ships, are already claimed as a success of the previous
iteration of the NDS [13], as well as initiatives in other
countries [41]. Why then, is there reticence among
policy-makers to integrate pill testing into current
Australian policy and practice?
This conservativism is symptomatic of a larger malaise
in Australian crime control, where in recent decades, drug
policy can be described as fragmented and contradictory
[45–47]. Similar to the penal policies in the UK and USA
in the late 20th century, Australian policy has been in-
creasingly volatile and incoherent, fluctuating—often
abruptly—between what Garland ([46]:450–9) charac-
terises as adaptive strategies, focused on prevention and
partnerships, and strategies of denial, which stress en-
hanced state control and expressive punishment. These
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swings are the result of the normalisation of high crime
rates and the state’s acknowledgment of their inability to
remedy this problem, creating a predicament for govern-
ments [46, 47]. As explored by O’Malley ([45]:181), this
predicament is shaped by a ‘recurring ambivalence’ where
governments seek to divest themselves of the chief re-
sponsibility for the delivery of crime control but recognise
the political consequences of doing so. This is an enduring
dilemma that helps to explain the fragmented and contra-
dictory nature of recent policy. Indeed, the essence of Gar-
land’s argument remains as valid as it did more than
20 years ago as contemporary governments continue to
struggle with various ‘crime problems’ (e.g. illicit drugs), in
a politicised policy and social landscape where the state is
‘confronted by its own limitations’ ([46]:462), manifest in
the perceived failure of criminal justice agencies and the
state generally to control crime.
Garland’s framework resonates further with Australian
drug policy where, in an attempt to decentralise control
but without undermining law and order agenda, politi-
cians and other key actors have altered the discourse of
drug policy and criminal justice debate by focusing on
the effects of drug use rather than its causes [45, 47].
For example, a recent national campaign features
content illustrating the effects of illicit drugs on victims,
describes the costs for the community and draws on
community fears of crime [50]. This discursive shift has
several implications for how drug use is understood and
regulated by the state. Firstly, this approach shows that
while adaptive strategies are possible, such as prevention
initiatives and partnerships between police and health-
care providers, for certain groups of offenders (i.e. drug
users), they are often ‘politically difficult and institution-
ally radical’, susceptible to moral opposition, failures of
political will and conflicts of partisan politics ([47]:348,
[51]). This results in policy that is inconsistent and
vulnerable to changing political and public interests.
Secondly, by focusing on the effects on victims and
the community and exposing debate to the vagaries of
politics and the media, this approach positions the needs
of society against those of the individual. Bull and
colleagues [52] argue that this sets a path for policy
where the objectives of support services and police con-
flict, and where harm minimisation goals become linked
to more intensive, zero-tolerance policy, reinvigorating
the debate about drugs as a problem of moral values.
Placing the harms to society in opposition to, or above
the harms to users, has the added consequence of the
exclusion or ‘othering’ of drug users, in effect curtailing
notions of social citizenship [46]. This has a much
broader bearing on our understanding of crime and its
control, not merely drug policy, as it creates a tension
between two contradictory criminologies: of ‘the self ’
(where the offender is rational and unremarkable) and of
‘the other’ (who is the dangerous outcast) [45, 47]. This
duality produces two distinct but related possible re-
sponses by the state: denial of responsibility for the
problem and the increased use of punishment as evi-
dence of ‘doing something’. This article shows that the
Australian Government appears to have employed both
responses in relation to the problem of party-drugs, with
consequences for pill testing initiatives.
The challenges posed by pill testing reflect broader
difficulties faced by policy-makers in balancing the goals
and perceptions of public health and criminal justice re-
sponses to drugs. These stem partly from the duality of
Garland’s criminologies, where despite conceptualisation
of the ordinary, rational offender, for certain crimes such
as drug use the field of crime control is largely shaped
by a ‘collective experience of…insecurity’ regarding the
‘other’ ([47]:347). Policy then, is often emotive, domi-
nated by campaigns displaying graphic imagery of abuse,
dependence and addiction [50, 53]. Similarly, calls for
reform are often used by politicians and the media as
opportunities to (re)activate moral debates. A legacy of
the 20th century is that the drug problem is seen as a
‘war’ to be won [24], so in-line with increased anxiety
about crime generally, drug policy has become a political
tool through which zero-tolerance principles have flour-
ished. For instance, research evaluations of recent adver-
tising campaigns reveal most participants reported
abstinence as the primary message conveyed [51]. The
government has, in effect, displaced responsibility to
users and their families to reduce drug-harms by avoid-
ing ‘bad choices’ or ‘just saying no’. This has followed a
period of largely conservative policy-making over-
whelmed by supply reduction strategies, with far greater
funding (65%) directed to law enforcement (e.g. roadside
testing, diversion), compared with harm reduction initia-
tives (2.2%) [15]. In relation to party-drugs, this has
meant that while some valuable programs have been im-
plemented, including the provision of ‘chill-out’ spaces
and medical services at events [54], overall, programs for
users have been limited. Moreover, while there is merit
in an economic argument, the power of this data is its
demonstration of an inability to control crime, the exclu-
sion of users and a punitive approach that, despite evi-
dence of its ineffectiveness [55, 56], is ‘too inscribed and
too politically potent to be easily dismantled by rational
critique’ ([46]:450). However, historically, pragmatic
reform in the area of Australian drug policy is possible.
Pragmatism: looking back to move forward?
As noted in the introduction, Australia’s drug policy
domain is contested. In contrast to punitive criminal just-
ice strategies, there have been initiatives successfully
trialled and implemented nationally that follow principles
of harm minimisation and public health. These examples
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are central to the arguments presented herein, because
they demonstrate effective praxis, as well as give shape to
the theoretical lens through which this paper is viewed.
Specifically, they address what Rhodes terms the ‘risk en-
vironment’ [43], that is, the need for emphasis on public
health to drive discourse and action away from exclusively
targeting theories of individual pathology, toward recogni-
tion of the social and environmental influences on behav-
iour and how problematic activities such as drug use
might be better managed through more pragmatic means
and cooperation. Drawn from research on HIV infection,
Rhodes’ framework [43] is particularly instructive because
it can be used to better understand both the epidemiology
of drug use, as well as how policy-makers, practitioners
and the community might work together to reduce the as-
sociated harms. It highlights the need to share responsibil-
ity for tackling drug use across the community, given that
drug-related harm intersects with criminal justice issues,
health, vulnerability and various social problems—com-
plex challenges faced by young people that require inter-
disciplinary and comprehensive responses. For example,
while not without its own criticisms, the introduction of
the Illicit Drug Diversion Initiative (IDDI) in 1999 offi-
cially signalled the utility of an operational relationship be-
tween police, health and support agencies [57]. The IDDI
was created to reconcile tensions between these sectors,
establish a more positive relationship and develop best-
practice in responding to drug use. Among a range of re-
habilitation and support programs, the IDDI also fostered
development of several harm reduction-oriented policing
strategies for local law enforcement, including Arrest Re-
ferral Schemes, where police refer minor drug offenders
to assessment and education services, in lieu of criminal
conviction, which research indicates is beneficial for police
and leads to subsequent harm reductions (e.g. fewer days
in incarceration) and increased support-seeking behaviour
among drug users [52, 58, 59].
Another positive collaboration was marked by the
introduction of Needle Syringe Exchange Programs
(NSEPs) and the Medically Supervised Injecting Centre
(MSIC) in Sydney, the largest capital city in Australia,
located in New South Wales (NSW). The NSEPs were
first trialled in 1986 [60], with the MSIC established in
2001 [52]. While, historically, there was conflict between
police and health workers linked to these initiatives,
legislative reforms and changes to NSW police operating
procedures encouraged police to ‘exercise discretion;
work collaboratively and develop a positive relationship
with local NSEPs; and promote the legal operation and
positive outcomes of NSEPs to the wider community’
([52]:311). These changes complemented policy reform
within NSW police, where overdose policies were
amended to consider community interest and avoid pur-
suit of minor possession charges in non-fatal overdoses,
reforms subsequently adopted by all other states and ter-
ritories [52]. This has contributed to arguably more ef-
fective responses to drug use (see p.12). However, these
strategies are not without fault, nor does reform occur
in a vacuum, often affected by economic, social and wel-
fare policies and community attitudes within a wider polit-
ical context. Consequently, making assumptions about the
value of pill testing based solely on the introduction of the
NSEP and MSIC is inappropriate. While indicative of
more pragmatic responses to drug use (e.g. heroin), there
were specific conditions that led to their introduction,
which are temporally distal from the current context and
argument presented. Primarily, the motivation for these
initiatives came from general concerns regarding public
health and the threat posed by HIV, related to the lack of
access to safe injecting equipment and/or spaces and
harms associated with needle-sharing [61]. These policies
were not necessarily about supporting drug users, but
avoiding an HIV epidemic. It is crucial then to acknow-
ledge that similar momentum has not developed for pill
testing, where drug use remains an ‘us and them’ problem
and users are socially excluded.
Nonetheless, these are examples of pragmatic re-
sponses that sought to reduce drug-related harms, as
well as foster cross-sectoral partnerships. Moreover,
there is evidence some of these initiatives and reforms
occurred during the ‘Howard era’, whose term of Liberal-
National coalition (centre-right liberal conservative) gov-
ernment spanning more than 10 years (1996–2007) is
usually associated with zero tolerance [62]. Alex Wodak,
Director of the Alcohol and Drug Service at St Vincent’s
Hospital in Sydney, argues the ‘tough on drugs’ narrative
and opposition to harm reduction that came to be asso-
ciated with the Howard Government did not unilaterally
translate into practice [63]. While Commonwealth
funding was increased for abstinence-oriented treatment
and support services [64], the Howard Government con-
temporaneously delivered—albeit discreetly—enhanced
funding for NSEPs [63]. The lessons learned from the
NSEPs are discussed further below, but it is clear that,
ideologically, much more can be garnered from this and
other examples. The message is that, although challen-
ging, it is possible to pragmatically respond to drug use
within a heavily politicised policy environment, by better
understanding the nature of the problem and the
responsibility to address it.
Results: Key indicators of the need for a more
pragmatic approach
Since the emergence of dance-music culture in
Australia, a variety of drugs including ecstasy and meth-
amphetamines have been associated with this scene,
used by young people to enhance their experiences [65].
The most recent National Drug Strategy Household
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Survey (NDSHS) report in 2016 revealed 11.2% of
Australians aged 14 years and over have ever tried ec-
stasy with 2.2% reporting use in the last 12 months [19].
Data are similar for use of methamphetamines with 6.3%
reporting lifetime use and 1.4% revealing recent use [19].
Although these figures are lower than other western
nations [44, 66], and demonstrate stable or declining
rates of use, they reveal that more than 2.2 million
Australians have used ecstasy, and more than 1.3 million
have used methamphetamines in their lifetime. However,
it is not the numeric value but the location and nature
of use and associated harms that are of most concern.
Firstly, although not representative, a sample drawn
from the Ecstasy and Related Drugs Reporting System
(EDRS) identified that up to 70% of this use occurs
within clubs, dance-parties and music festivals [26]. This
is supported by the representative NDSHS data,
confirming them as important sites of analysis [19].
Secondly, there appear to be significant shifts in the
forms of drug use in the dance-party scene, particularly
among youth. This follows national trends, where those
aged 20–29 are the most likely to have consumed illicit
drugs generally, with more than a quarter (28%) report-
ing use in the previous 12 months [19]. Internationally,
the prevalence of ecstasy and methamphetamine use
among youth attending dance-parties is greater than
general population rates [37, 42], which also describes
the Australian experience [3]. Indeed, while overall rates
of use of both substances reported in 2013 and again in
2016 represent a decline from peaks in 2007, these
results mask the level of drug use among specific youth
subgroups which has remained stable or increased.
Sindicich and Burns [26] report that although recent
users of ecstasy largely reported consistent use, typically
two or three times a month, a quarter of the sample
reported an increase to weekly use. During this period,
similar patterns were identified among current metham-
phetamine users, with the use of the more potent ‘ice’
more than doubling, and a comparable increase
observed in the proportion of users who consumed
daily/weekly [65]. Although ecstasy use has not reached
the levels observed in 2007, methamphetamine use has
surpassed these benchmarks [19]. Again, the value of
these findings is less in the absolute numbers and more
about the behavioural patterns they suggest: chiefly,
increased use of more potent substances, concentrated
among a novel youth subgroup.
Equally important is the capacity of monitoring sys-
tems to respond to changes in drug markets, in order to
track and respond to new groups of users. The primary
form of monitoring in Australia is the EDRS, which
compares interviews with regular ecstasy and other drug
users and key professionals, with several key indicators
to map trends in drug use, price, purity and availability.
In 2015, the EDRS revealed that ecstasy and metham-
phetamines were readily available and primarily of mod-
erate quality/purity [26]. For ecstasy, although a third of
users reported purity as moderate (35%), with a further
20% reporting high-purity pills, more than a quarter per-
ceived levels to be fluctuating (29%). For methamphet-
amines, the data followed national trends with a shift
toward ice, which was far more accessible (97% reported
either ‘easy’ or ‘very easy’) and where purity was rated as
either moderate (34%) or high (46%), although this form
also experienced the greatest perceived fluctuation (15%)
[26]. These figures describe accessible drugs that vary
markedly in quality/purity, which is problematic as even
moderate variations exacerbate already significant risks.
Caution must be taken when interpreting these figures
though, as they relate to relatively new and capricious
drug use settings (e.g. music festivals). The EDRS also
relies on data from sentinel groups of regular users
(approx. 800 in 2016), as well as professionals (e.g. GPs,
police, treatment providers) who interact with them, to
determine consumption patterns [26]. Previous research
[24, 25] has revealed that party-drug users, however, are
a heterogeneous group of consumers, many of whom
are educated, socially and economically stable and who
rarely come into contact with criminal justice, treatment
or support services. Many do not consider themselves
more than ‘occasional’ users [25], so are not captured by
existing data collections. In addition, although cross-
sectional surveys are effective in evaluating users’ per-
ceptions of consumption habits and online marketplace
analysis (e.g. the recently shutdown ‘Silk Road’) [67] has
emerged as a contemporary method to track drug sales,
because drug samples are not scientifically tested, these
perceptions and sales cannot be linked with what is
actually consumed [68].
Wastewater analysis is another nascent form of moni-
toring used in the last decade in Australia [69, 70] which
provides data about the level and type of drug use
through testing of excreted drug residues in sewage/
wastewater. This process is similarly limited in its scope
to fully examine and minimise the harms associated with
party-drug use. To date, these tests have focused primar-
ily on defined geographical areas and broad population
analyses (e.g. large catchment areas in capital cities and
rural areas [69]), which prevents the linking of compos-
itional data to what young people think they are taking,
and sensitivity to changes in consumption trends of par-
ticular groups. Although wastewater analysis has been
undertaken at Australian music festivals [71], again, only
small-scale population data can be collected as this
method is unable to record finer demographic detail. For
example, data on gender, age and ethnicity of users,
differences in route of administration, the number of
users (i.e. occasional use by many or heavy use by a few)
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and the different forms of drug used (e.g. ice versus
speed) cannot be distinguished using wastewater analysis
[72]. This method is further constrained by lag-times in
data collection and analysis, incomplete databases and
its retrospective approach, occurring once drugs have
been taken, making it less responsive to market changes
and less preventative in terms of the harms experienced
and individuals’ decisions to use drugs [67].
Another concern relates to the threats posed by
new psychoactive substances (NPS), which have
emerged in Australia [30, 68] following rapid rises in
Europe [12, 32, 73] and popularity at dance-parties and
music festivals. These substances, also known as analogues
or synthetics, are designed to mimic established drugs
[17] and often comprise new, untested chemicals used by
drug manufacturers to replace others either in short sup-
ply or banned through changes to possession, production
and importation laws. This means their contents and
effects are unpredictable, placing users and the commu-
nity at further risk of harm due to an ever-increasing
number of ‘unknowns’. This risk is demonstrated in re-
cent findings from the USA and Canada, where several
studies identified the introduction of fentanyl in the illicit
drug market [74, 75]. Specifically, evidence suggests a wide
range of pills (e.g. MDMA) and other drugs (e.g. metham-
phetamine, cocaine) have been laced with fentanyl,
highlighting the potential danger of relying solely on exist-
ing practices and technologies, as often local laboratories
or other facilities (e.g. hospitals, police) do not have cap-
acity for fentanyl testing or detection of new analogues
[74]. While drug use cannot be conceptualised as ‘safe’,
greater knowledge of these substances arguably improves
policy and treatment options. In recognition of this, ques-
tions regarding NPS were first incorporated into the
NDSHS in 2013, where approximately 80,000 (0.4%) of
the population indicated lifetime use, primarily 20–29 year
olds [67]. This population has increased steadily since
[19], although levels of use are likely underreported as
these substances are characterised by psychoactive proper-
ties that imitate existing drugs. Users may therefore be un-
aware of what they are taking, confounding both
monitoring and treatment efforts. Although no deaths
linked to fentanyl have been confirmed in Australia, the
presentation of 10 drug-affected youth in one night at
Royal Perth Hospital in 2013 [30] demonstrates the devas-
tating consequences of new ‘batches’ of unknown sub-
stances. Pill testing then may serve as an additional
mechanism through which to maintain pace with shifts in
drug use trends and contribute to more effective preven-
tion and treatment. Certainly, pill testing cannot be a
stand-alone tool; rather, best practice would be its integra-
tion into the current NDS to provide both general data on
consumption trends and market fluctuations and specific
information to users to reduce drug-related harms.
Discussion: Research evidence: ‘What works?’
Like most debates about policy reform, a key question in
the rationale for pill testing is whether it ‘works’. The lit-
erature is complicated and, to date, no studies have fully
tested in a controlled way, whether pill testing reduces
harms. Most evaluations concern attitudinal change (e.g.
what people would do [20]), legal issues and the integrity
of various analytic procedures, with others describing
program features or contextually relevant praxis [76], so
although not within the scope of this paper, a large,
multi-site systematic review of testing practices is
needed. Nevertheless, part of the paradox of pill testing
comes from expectations of drug policy and practice
generally, where effectiveness is often measured in
language of abstinence. As a robust body of literature
has shown [48, 77], however, abstinence is a goal that
displays ignorance of reality. A much broader definition
is needed, which demarcates effectiveness more prag-
matically, as any strategy shown to improve public
health or reduce the prevalence or severity of drug-
related harms. For example, connecting users with
support services, increasing education and awareness,
monitoring market changes and encouraging avoidance
of dependence are strategies shown to be effective in
Europe [41, 77]. Despite this, like in the UK [10, 77],
Australian policy-makers have appeared to take limited
account of these findings. Only recently has meaningful
debate begun on some of these issues in an unprecedented
drug summit, convened in 2016 by the Australian Parlia-
mentary Group on Drug Policy and Law Reform
(APGDPDR). It is too early to gauge the full impact of the
summit, other than its symbolic value in bringing together
key stakeholders, and their collective agreement that the
current approach is not working [78]. It is logical then, to
seek further guidance on drug policy reform.
In many ways, Australia’s experience mirrors recent
trends in the Netherlands [41], Portugal [79], and
Switzerland [37], particularly in terms of rates of ecstasy
and methamphetamine use and the emergence of NPS.
Over the last 20 years, the political landscapes in these
countries have similarly been characterised by growing
concerns over the social exclusion and marginalisation
of drug users, sparking substantive policy reforms.
Although policy transfer is not ‘one-size-fits-all’, influ-
enced by community attitudes, individual rights, broader
political structures, and the different ways (drug) prob-
lems are experienced [77], much can be learned from
these examples. In Portugal, for instance, pill testing was
implemented alongside comprehensive changes to
policy, discourse and philosophy about their drug prob-
lem. Personal possession of all drugs was decriminalised
in 2001, following radical shifts in social thinking (akin
to Rhodes’ approach [43])––that conceptualised drugs as
a public health concern, leading to increased resourcing
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of prevention, treatment and social reintegration pro-
grams [80]. Although attitudes to drugs are more liberal
in Europe [41], suggesting caution in any comparative
analyses, the literature indicates that, in particular set-
tings, pill testing can reduce the prevalence of harms for
users, influence youth decision-making and positively
impact drug markets. In terms of the latter, pill testing
has been shown to affect the manufacture and distribu-
tion of pills [41, 81]. By accurately identifying drug
content and purity/potency, the Netherlands’ Drug
Information and Monitoring System (DIMS), for ex-
ample, has informed national warning campaigns, which
has pushed dangerous, low-quality substances from the
market [41, 81]. Another benefit has been, over time, the
composition of tested pills has begun to more closely
correspond with expectations [32, 76], increasing overall
drug-quality, while alleviating some of the strain on
under-funded healthcare and support agencies by
reducing the prevalence of overdoses and hospital
admissions [15].
Most notably, pill testing has been shown to positively
affect users’ behaviour, contradicting claims often used
as the rationale for criminalisation that ‘soft’ options
encourage increased uptake and use, particularly among
youth [68, 82, 83]. Evaluation of the chEckiT project in
Austria reported approximately half of users whose
drugs were tested indicated that information about qual-
ity/purity would influence their decision to take them
[36]. If presented with a negative result, two thirds
reported they would not consume their drugs and would
also warn friends against consumption [36, 76]. This
corresponds with research from the Netherlands [37],
which revealed no increases in the use of most party-
drugs (or poly-drug use) because of pill testing and
provision of drug information. This also supports evalu-
ations of the reforms in Portugal, where pill testing, as
part of a wider public health approach, in fact reduced
problematic use, related harms and burden on the just-
ice and healthcare systems [79, 80]. Similarly, when
users access testing sites (e.g. at festivals), it allows
health and support workers to establish contact with this
hard-to-reach population and provide advice about the
support available [34]. This is crucial as it is often the
first interaction these young people have with any type
of support service [31, 37], given they represent a diverse
and well-balanced cohort, who are less likely to come
into contact with the criminal justice or healthcare sys-
tems. Furthermore, party-drug users appear to be highly
receptive to harm reduction and prevention measures
and/or messages when they are delivered face-to-face
and by more trusted sources [42], even among
dependent and poly-drug users [37]. As found by several
studies, the contact users have with support workers,
combined with factual information concerning
individual drug purchases and other market information,
provide a strong foundation for subsequent health-
conscious behaviour [41, 84]. Because young drug users
often dismiss government messages as untrustworthy,
they are also better persuaded by well-informed peers or
professionals [40, 41]. This strategy has long-term bene-
fits, shown to increase users’ motivation for subsequent
participation in follow-up counselling sessions [32, 37],
providing impetus for support of peer-education and
peer-led interventions.
A final feature of pill testing is that it enables monitor-
ing of drug-forms, patterns of consumption and the
characteristics of users [37]. The party-drug scene is
typified by the use of a large range of substances, the
composition of which is expectedly variable and incon-
sistent. Widespread testing within this setting enables
collection of long-term trend data about what users are
actually taking, useful for identification of current mar-
kets and drug-taking methods [32, 42]. This would in
turn build academic research capacity, improve preven-
tion planning and enhance knowledge and research
methodology, through directly linking users’ perceptions
with their consumption rather than relying on self-
report or broad population studies. This may also influ-
ence existing supply and demand reduction efforts
where, for example, many users report reliance on online
networks and/or websites that provide more comprehen-
sive information on drug purity, availability and effects
than is available through official sources [82]. The dis-
semination of more accurate drug information from pill
testing, through these online channels (e.g. social media,
online forums), could identify and force out of the mar-
ket websites or dealers found to be sharing inappropriate
and/or incorrect information, which is likely impact
supply routes, helping police to direct their resources.
Beyond this, compared with retrospective analyses (e.g.
wastewater analysis), in situ pill testing has the capacity
to act as an early warning system to identify the emer-
gence of new drugs more quickly, which is critical given
the recent surge in NPS [73, 85]. Overall, these factors
allow policy-makers and support services to be more re-
sponsive to dynamic market shifts and build knowledge
for the development of targeted prevention initiatives. In
Australia, however, unquestionably drug policy debate is
over-shadowed by philosophical and moral conflict, so
for pill testing to be possible requires broader accept-
ance and a clear direction for its implementation.
Support in the Australian context
A number of policy models set out a way forward for
the introduction of pill testing, which has, in fact,
already been trialled in Australia, albeit briefly [86, 87].
In the ‘Enchanted Forest’ raves in South Australia from
2000 to 2001, a group of physicians with the backing of
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the Australian Medical Association (AMA), several harm
reduction non-government organisations (NGOs) and
the ‘understanding of local authorities’ examined ravers’
pills in an attempt to reduce consumption [88, 55].
Indicative of the contentious and fragile nature of drug
policy though, these trials were terminated after only a
short period by the Howard Government [86, 89].
Despite limited opportunity, the research was able to
identify large variations in pill composition, emergence
of new substances and discrepancies in police testing
procedures [88], providing a platform for more compre-
hensive follow-up, as well as indication of local-level
support from experts and health practitioners.
A wealth of empirical data also reveals considerable
community support for pill testing, challenging punitive
criminal justice responses to drug use. Several studies
[76, 90] and the 2013 NDSHS report [65] suggest many
Australians see little value in punitive sanctions (e.g.
imprisonment, increased fines) for drug use. Instead,
referral of users to treatment or education programs
appears the preferred response (approx. 45%), with only
drug manufacture and distribution perceived to warrant
harsh penalties. Drawing from a large (n > 2300) internet
survey of young Australians, Lancaster and colleagues
[76] report the majority back the implementation of pill
testing (82.5%), as well as other harm reduction initia-
tives (NSEPs 76%, ‘chill-out zones’ 65.6%). An even
greater level of support was reported in a survey con-
ducted at a major Australian music festival in 2016,
where most participants (86.5%) believed testing services
could help to reduce harm for users [3]. These findings
describe a cohort that values information and seeks to
engage in safer practices, regardless of whether they use
drugs. Notably, many youth also appear to translate this
drug knowledge into behavioural change, with an Aus-
tralian study finding more than three-quarters of regular
ecstasy users would not take an ‘unknown pill’ [91]. A
similar result was identified in a more recent sample of
users at Australian dance-parties or music festivals [29],
where 90% reported seeking information about drug
contents in the last 12 months. Most of these respon-
dents (60%) had encountered unexpected substances or
problems with drug purity during this period, which mo-
tivated them to alter their behaviour with more than half
warning friends (51%), many deciding not to consume
their drugs (39%) and more than a quarter reducing the
amount they consumed (28%) [29]. Most respondents
also reported they would use a form of self-testing
(94%), onsite event testing (94%) or a fixed-site (i.e.
‘drop-in’) service, and valued services that provided
comprehensive, individual feedback rather than only
when dangerous results were found. This reinforces
previous claims that young people can be persuaded to
make rational decisions and are willing to use testing
services, which may elicit positive behavioural change at
the time of use, reducing some drug-related harms [84].
If pill testing is to be discussed constructively, the final
piece of the puzzle is the maintenance of cross-sectoral
partnerships. Strong links must be (re)forged between
government, police, AOD treatment services and
research institutions, as well as with nightclub and music
festival industries. There is already movement from
within the latter for such partnerships [92, 93]. However,
as noted by these groups, the success of any initiative is
contingent upon the extent of support from key stake-
holders––health, police and government––to serve as
‘drug policy actors’ [11], [5], [94]. These agencies need
to lead innovation in thinking and practice, as there
remains considerable political capital in the debate that
will otherwise impede creation of better drug policy. For
example, the police are a critical element in any
approach, as to be meaningful, policy must avoid the
trap of net-widening and tacitly supporting harm reduc-
tion, while allowing police to ‘pick up’ users elsewhere
within the system [10, 79]. Harm reduction-oriented
policing initiatives must also be clearly defined, well-
resourced and widely supported given police play a com-
plex role as an initial contact for many users and conduit
for providing case management, links to drug treatment,
job training, housing assistance, legal advocacy and
counselling [60]. There have been examples of successful
initiatives, one of which I will discuss briefly before
concluding.
The aforementioned NSEPs and MSIC in Sydney are
examples of positive law enforcement-health partner-
ships. Radical at the time, the trajectory of the relation-
ships between police and healthcare and treatment
providers, support services and NGOs provides fertile
ground for discussion and the foregrounding of future
reforms, as there was a discernible shift in thinking and
application that led to positive outcomes for the com-
munity (e.g. reduced public drug use and associated ‘lit-
ter’) and for users (e.g. safer spaces and access to
treatment and support). Indeed, the response to drug
use in this particular context shifted from a situation of
law enforcement opposition and policing practices that
largely undermined the operation of these programs, to
one where legislative reforms and organisational policy
changes facilitated the effective operation of treatment
and support services and their ongoing cooperation with
NSW police [51]. For instance, possession of injecting
equipment or drug paraphernalia was an offence, creat-
ing obvious risks for individuals seeking assistance, as
well as the NSEPs or MSIC themselves, as organisations
that dispense drug-related equipment and provide infor-
mation regarding their use, while seeking to create a
safer, supervised space for people to use their drugs
without police interference. In NSW, the solution was
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reform of the relevant drug control legislation [95],
which permitted health and support service personnel
within the NSEPs to provide equipment and information
to users, or a supervised space in the MSIC without ex-
posing them to prosecution under the Drug Misuse and
Trafficking Act (NSW) 1985 [96]. A Commissioner’s
Instruction was also circulated in NSW in 1988, which
shaped police operational practice to follow harm reduc-
tion principles, directing police to avoid unnecessary
patrols of the areas surrounding the NSEPs and MSIC
and to use discretion to prevent the discouragement of
users seeking help, while ensuring dealers did not take
advantage of the perceived leniency [51].
In summary, what was created was a more supportive,
public health-focused environment where users were
exempted from prosecution and legal constraints related
to drug use and/or possession while on the premises and
where discretion was applied in policing the surrounding
area. To do otherwise would have undermined the pur-
pose of these important and ongoing policy initiatives,
analogues of which have since been implemented in
most other jurisdictions. Though there are some clear
differences in the rationale and application of these ini-
tiatives, the success of NSEPs and the MSIC suggests
there is scope for a comparable response to party-drug
use, with ongoing collaboration and engagement be-
tween law enforcement and health services facilitated
through an integrated policy comprising pill testing.
Conclusion: worth the test?
The problem of drugs—both illicit and illicitly used—is a
feature of contemporary social life, for which alternative
strategies are needed to reduce the harms for users, their
families and the wider community. From analysis of key
data and the wider literature, it is evident certain forms
of problematic party-drug use are concentrated among a
small proportion of young club and music festival
attendees, challenging the limits of current Australian
drug policy and practice. In these dynamic spaces, party-
drugs such as ecstasy and methamphetamines are readily
available and widely used, with recent evidence of in-
creased consumption of more potent forms (i.e. MDMA
and ice) by young people. Pill testing is needed to moni-
tor the quality/content of drugs used, as well as the
rapid rise of NPS, which pose significant risks to users
and those who share the social spaces of clubs and
music festivals.
Pill testing is not a novel concept; in fact, its objectives
are consistent with Australia’s NDS, as well as several
extant programs. Notwithstanding a strong philosophical
rhetoric of harm minimisation, in practice, government
policy remains conservative in its approach, prioritising
law enforcement strategies and zero-tolerance policies.
This is despite evidence of their limited effectiveness, as
well as growing support from experts, academics and
the community highlighting the need for an alternative
approach. Several national surveys and empirical studies
have shown that although drug use is illegal, there is a
widespread support that harm reduction and public
health-focused strategies are, at least, equally worth-
while. Nevertheless, achievement of these goals requires
movement beyond entrenched philosophical and moral
arguments, which have historically played a part in pro-
ducing fragmented and contradictory drug policy.
Drawing from Garland [46, 47] and O’Malley [45], it is
clear the Australian government is concerned that
retreat from a tough stance represents a capitulation in
an already failed ‘war on drugs’. This article then shows
the need to move away from the politics of drug policy
toward more evidence-based strategies to maximise the
safety of young people that choose to use drugs who, if
given the opportunity to do so more safely, will likely
‘grow out’ of use, without the stigma and harms
associated with criminalisation. While unambiguous,
zero-tolerance messages are unrealistic and disregard
contemporary patterns of youth drug use. In contrast,
pill testing offers an alternative message; that drug use is
dangerous, and informing users about what they are tak-
ing and the risks not only demonstrates social responsi-
bility for this marginalised group but also that young
people have the capacity for rational decision-making
and may desist from drug use because they see the risks
for the first time.
Taking a more pragmatic view of harm reduction by
expanding measures of effectiveness beyond abstinence,
to include increased awareness, reduced consumption
and other behavioural changes (e.g. peer information
sharing), this article has argued pill testing can be an
effective harm reduction tool in a range of contexts, with
support for its implementation in Australia and oppor-
tunities for its broader application in other countries
and drug use settings. Evidence suggests pill testing
offers several advantages, facilitating long-term data cap-
ture, contributing to knowledge on the nexus between
consumption habits and perceptions of use, positively
influencing drug markets and overall drug quality, while
also enabling essential contact between users and sup-
port services. Pill testing also encourages cross-sectoral
partnership, greater social inclusion and youth agency
(including peer-education and engagement), where the
task of harm reduction is understood as a shared social,
public health responsibility. Indeed, Australian policy-
makers should look to and learn from other policy set-
tings, notably Portugal, with the similarly broad aim of
lessening the burdens on healthcare systems, over-
crowded criminal justice institutions and families, while
also reducing problematic use. In this way, pill testing
serves as a platform for more nuanced discussion of
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drug policy ideas and applications, particularly the need
for innovative responses, to avoid the deaths of more
young Australians. Australia is in the position to, at the
very least, conduct comprehensive trials of pill testing
and related strategies (e.g. DIY pill testing kits), to en-
able evidence-based decision-making. Pill testing cannot
eliminate the harms of drug use, but it is not intended
to. It represents a model that best functions as one part
of a much wider harm reduction strategy, to provide less
punitive and more pragmatic responses to drug use for
the protection of a generation of young club and music
festival attendees, clearly establishing its worth in the
Australian drug context.
Endnotes
1This is likely a response to the increased use of
‘sniffer-dogs’ at recent music festivals, despite consider-
able criticism and research evidence of their ineffective-
ness [27].
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